0001209191-21-007550.txt : 20210203
0001209191-21-007550.hdr.sgml : 20210203
20210203200035
ACCESSION NUMBER: 0001209191-21-007550
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210201
FILED AS OF DATE: 20210203
DATE AS OF CHANGE: 20210203
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Goater Jeff
CENTRAL INDEX KEY: 0001656435
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38459
FILM NUMBER: 21588244
MAIL ADDRESS:
STREET 1: C/O SURFACE ONCOLOGY, INC.
STREET 2: 50 HAMPSHIRE STREET, 8TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Surface Oncology, Inc.
CENTRAL INDEX KEY: 0001718108
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 50 HAMPSHIRE STREET, 8TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-714-4096
MAIL ADDRESS:
STREET 1: 50 HAMPSHIRE STREET, 8TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-02-01
0
0001718108
Surface Oncology, Inc.
SURF
0001656435
Goater Jeff
C/O SURFACE ONCOLOGY, INC.
50 HAMPSHIRE STREET, 8TH FLOOR
CAMBRIDGE
MA
02139
1
1
0
0
Chief Executive Officer
Common Stock
2021-02-01
4
M
0
2500
3.18
A
264500
D
Common Stock
2021-02-01
4
S
0
2500
10.687
D
262000
D
Stock Option (Right to Buy)
3.18
2021-02-01
4
M
0
2500
0.00
D
2030-02-03
Common Stock
2500
249500
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 18, 2020.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.32 to $11.19, inclusive. The reporting person undertakes to provide to Surface Oncology, Inc., any security holder of Surface Oncology, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
This option shall become exercisable in equal monthly installments over four years following January 21, 2020, so long as the reporting person remains an employee or other service provider of the Company on such dates.
/s/ Jessica Fees, as Attorney-in-Fact
2021-02-03